Fact.MR, a provider of competitive intelligence and market research: The antimicrobial susceptibility market tests is projected to reach US$ 3,285.8 million in 2022 and grow at a remarkable compound annual growth rate (CAGR) of 5.7% over the forecast years of 2022–2032, according to Fact.MR, a supplier of market research and competitive information.
The frequency of infectious illness outbreaks, such as those brought on by Shigella, Neisseria gonorrhea, Neisseria meningitides, and Salmonella serotype Typhi, has increased as a result of unsanitary surroundings and a lack of safe drinking water. Doctors are now more aware of the importance of performing antibiotic susceptibility tests (ASTs), which are expected to propel the market for antimicrobial susceptibility testing and are now a crucial component of clinical microbiology labs.
Download Free Sample Copy of This Report
https://www.factmr.com/connectus/sample?flag=S&rep_id=4334
The expanding importance of drug discovery, the rise in chronic illnesses, and the development of antibiotic resistance have also led to an increase in the usage of antimicrobial susceptibility tests by pharmaceutical and biotechnological businesses. Therefore, this trend is expected to support the market for antimicrobial susceptibility testing over the forecast period.
The availability of a range of manual and automated solutions that provide testing results faster and with greater accuracy has given major industry players a new chance to participate in the antimicrobial susceptibility testing market. This opportunity will create significant growth opportunities throughout the projected period and propel the market's expansion.
What’s Driving Demand for Antimicrobial Susceptibility Tests?
The increasing prevalence of microbial resistance is a significant factor driving the growing demand for antimicrobial susceptibility testing, contributing to the expansion of the global market. Antimicrobial resistance is a complex issue affecting people of all ages and demographics worldwide.
Data from Fact.MR reveals that antimicrobial resistance leads to approximately 2 million infections and 23,000 deaths annually in the United States, while antibacterial-resistant diseases cause an estimated 25,000 fatalities each year in Europe. This growing threat underscores the urgent need for innovative broad-spectrum antibacterial treatments.
Government funding and strategic initiatives further bolster the development of these tests. For example, the World Health Organization (WHO) and other non-profit funding organizations have proposed a new antimicrobial innovation funding model. This framework includes government-financed grants and reward mechanisms to support early-stage research, interim clinical trial results, and final product outcomes, fostering advancements in antimicrobial innovation.
Country-Wise Insights
The antimicrobial susceptibility testing market in North America is projected to grow at a CAGR of 6.0% between 2022 and 2032.
This growth is attributed to the increasing demand for susceptibility testing to guide empiric treatments, rising R&D efforts focused on antimicrobial resistance testing systems, and the growing use of these tests in medical laboratories.
Additionally, North America is home to many leading companies in the field. Key players are prioritizing expansion to enhance their networks and capabilities, further propelling market growth across the region.
Competitive Landscape
Prominent manufacturers in the antimicrobial susceptibility test market include Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, Conda, Creative Diagnostics, HiMedia Laboratories, Alifax Holding S.p.A., and Biotron Healthcare.
Leading players in the global market are actively engaging in strategies such as product launches, regulatory approvals, technological advancements, acquisitions, and joint ventures. These initiatives are expected to drive growth in the global antimicrobial susceptibility test market.
- In April 2022, bioMérieux acquired Specific Diagnostics, reinforcing its commitment to combating antimicrobial resistance.
- In August 2022, BD, a global leader in medical technology, announced a commercial collaboration with Accelerate Diagnostics, Inc., enabling both companies to address the global challenge of antimicrobial resistance more effectively.
Fact.MR's recent report provides comprehensive insights into the pricing strategies of key manufacturers, regional sales growth, production capacities, and potential technological advancements in the antimicrobial susceptibility test market.
Segmentation of Antimicrobial Susceptibility Test Industry Research
-
By Product :
- Kits, Reagents, & Consumables
- Automated Test Systems
- Culture Media
-
By Method :
- Broth Dilution Method
- Rapid Automated Method
- Disk Diffusion Method
- Gradient Diffusion Method
- Molecular Testing Method
-
By Test Type :
- Antibacterial
- Anti-parasitic
- Antifungal
- Others
-
By Application .
- Clinical Diagnosis
- Drug Discovery and Development
- Others
-
By End-user :
- Diagnostic Laboratories and Hospitals
- Research and Academic Institutes
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations
-
By Region :
- North America
- Latin America
- Europe
- East Asia
- South Asia & ASEAN
- Oceania
- MEA
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com
Comments
0 comment